Y. Khor (Melbourne (VIC), Australia), S. Jouneau (Rennes Cedex, France)
6-minute walk test in fibrotic interstitial lung disease (ILD)
Y. Khor (Melbourne, VIC, Australia), K. Johannson (Calgary, AB, Canada), V. Marcoux (Saskatoon, SK, Canada), J. Fisher (Toronto, ON, Canada), D. Assayag (Montreal, Quebec, Canada), N. Khalil (Vancouver, BC, Canada), J. Morisset (Montreal, Quebec, Canada), M. Kolb (Hamilton, ON, Canada), C. Ryerson (Vancouver, BC, Canada)
|   |
A modified blood cell GAP (cGAP) to prognosticate outcomes in IPF
M. Kreuter (Heidelberg, Germany), J. Lee (Denver, United States), A. Tzouvelekis (Patras, Greece), J. Oldham (Sacramento, United States), P. Molyneaux (London, United Kingdom), D. Weycker (Brookline, United States), M. Atwood (Brookline, United States), K. Kirchgässler (Basel, Switzerland), T. Maher (Los Angeles, United States)
| |
Evaluation of home monitoring for patients with interstitial lung disease during the COVID-19 pandemic
G. Nakshbandi (Rotterdam, Netherlands), K. Moor (Rotterdam, Netherlands), A. Vorselaars (Utrecht, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
| |
Digital device usage for home-monitoring in interstitial lung disease [ILD]:mixed-method survey
R. Shuttleworth (Exeter, United Kingdom), M. Althobiani (London, United Kingdom), A. Duckworth (Exeter, United Kingdom), J. Conway (London, United Kingdom), J. Dainton (Exeter, United Kingdom), S. Lines (Exeter, United Kingdom), J. Mandizha (Exeter, United Kingdom), A. Jorge Da Ponte (Exeter, United Kingdom), C. Scotton (Exeter, United Kingdom), M. Gibbons (Exeter, United Kingdom), A. Russell (Exeter, United Kingdom)
| |
Remote Early Identification of Disease Progression in Connective Tissue Disease related Interstitial Lung Disease (CTD-ILD) using Digital Patient Empowered Monitoring
W. Ng (Dublin, Ireland), R. O'Farrell (Dublin, Ireland), A. Schweikert (Dublin, Ireland), D. Howard (Dublin, Ireland), L. Durcan (Dublin, Ireland), K. Hurley (Dublin, Ireland)
| |
Interstitial Lung Diseases Virtual Clinics: a novel medical education method during pandemic times
B. Varela (Ciudad Autónoma de Buenos Aires, Argentina), G. Tabaj (Buenos Aires, Argentina), L. Sheridan (Buenos Aires, Argentina)
| |
The Brainomix automated e-ILD CT algorithm outperforms forced vital capacity in predicting outcomes for patients with idiopathic pulmonary fibrosis
C. Rennison-Jones (Oxford, United Kingdom), S. Gerry (Oxford, United Kingdom), G. Gupta (Oxford, United Kingdom), O. Joly (Oxford, United Kingdom), E. Greveson (Oxford, United Kingdom), G. Harston (Oxford, United Kingdom), A. Devaraj (London, United Kingdom), P. George (London, United Kingdom)
| |
Reticulation is associated with the risk of disease progression in interstitial lung diseases
M. Mononen (Kuopio, Finland), E. Saari (Kuopio, Finland), H. Hasala (Tampere, Finland), H. Kettunen (Kuopio, Finland), S. Suoranta (Kuopio, Finland), H. Nurmi (Kuopio, Finland), J. Randell (Kuopio, Finland), J. Laurikka (Tampere, Finland), T. Uibu (Tampere, Finland), M. Kärkkäinen (Kuopio, Finland), T. Selander (Kuopio, Finland), H. Koskela (Kuopio, Finland), R. Kaarteenaho (Oulu, Finland), M. Purokivi (Kuopio, Finland)
| |
Characterization of Idiopathic Pulmonary Fibrosis (IPF) and Combined Pulmonary Fibrosis and Emphysema (CPFE) using Respiratory Oscillometry
J. Wu (Toronto, Canada), J. Xu (Toronto, Canada), C. Nohra (Toronto, Canada), A. Vasileva (Toronto, Canada), W. Binnie (Toronto, Canada), S. Shapera (Toronto, Canada), J. Fisher (Toronto, Canada), C. Ryan (Toronto, Canada), M. Mcinnis (Toronto, Canada), Z. Hantos (Toronto, Canada), C. Chow (Toronto, Canada)
| |
Preliminary data of the risk stratification score (RISE) prospective, multi-centre, 3-year, validation trial in idiopathic pulmonary fibrosis.
G. Manzetti (Rome, Italy), K. Hosein (London, Canada), M. Cecchini (London, Canada), K. Kwan (London, Canada), M. Abdelrazek (London, Canada), M. Zompatori (Milan, Italy), P. Rogliani (Rome, Italy), M. Mura (London, Canada)
| |
Can FDG-PET/CT imaging be used to prognosticate in Interstitial Lung Disease? A prospective study of the relationship between FDG-PET/CT measurements and quality of life.
L. Jordon (Cambridge, United Kingdom), B. Ganeshan (London, United Kingdom), I. Nadeem (Luton, United Kingdom), L. Hoy (London, United Kingdom), N. Mahdi (Luton, United Kingdom), J. Porter (London, United Kingdom), A. Groves (London, United Kingdom), T. Win (Stevenage, United Kingdom), I. Nadeem (BEDFORD, United Kingdom)
| |
Interstitial lung abnormality evaluated by automated quantification system: prevalence and progression rate
J. Oh (Seoul, Republic of Korea), G. Kim (Los Angeles, United States), J. Song (Seoul, Republic of Korea)
| |
Pleuroparenchymal Fibroelastosis impact in Idiopathic Pulmonary Fibrosis outcomes
N. Faria (Porto, Portugal), S. Dias (Porto, Portugal), M. Silva (Porto, Portugal), D. Carvalho (Porto, Portugal), A. Carvalho (Porto, Portugal), P. Mota (Porto, Portugal), N. Melo (Porto, Portugal), H. Bastos (Porto, Portugal), A. Alexandre (Porto, Portugal), C. Moura (Porto, Portugal), S. Guimarães (Porto, Portugal), O. Sokhatska (Porto, Portugal), R. Cunha (Porto, Portugal), J. Pereira (Porto, Portugal), A. Morais (Porto, Portugal)
| |
Coexistence of pleuroparenchymal fibroelastosis and hypersensitivity pneumonitis – analysis of prognostic impact
S. Dias (Porto, Portugal), N. Faria (Porto, Portugal), M. Silva (Porto, Portugal), D. Carvalho (Porto, Portugal), A. Carvalho (Porto, Portugal), P. Caetano Mota (Porto, Portugal), N. Melo (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Terras Alexandre (Porto, Portugal), C. Souto Moura (Porto, Portugal), S. Guimarães (Porto, Portugal), O. Sokhatska (Porto, Portugal), R. Cunha (Porto, Portugal), J. Pereira (Porto, Portugal), A. Morais (Porto, Portugal)
| |
Microbiology profile of BAL in interstitial lung disease patients
E. Palmer (Budapest, Hungary), A. Nagy (Budapest, Hungary), T. Nagy (Budapest, Hungary), N. Toth (Budapest, Hungary), L. Polivka (Budapest, Hungary), K. Vincze (Budapest, Hungary), N. Eszes (Budapest, Hungary), A. Bohacs (Budapest, Hungary), V. Müller (Budapest, Hungary)
| |
Cardiopulmonary Exercise Test Could Provide Prognostic Value of 1-year Mortality in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis: A Real-World Experience
P. Fu (Taichung, Taiwan), Y. Cheng (Taichung, Taiwan)
| |
Fibroblast activation protein and disease severity, progression and survival in IPF
T. Prior (Aarhus, Denmark), N. Hoyer (Copenhagen, Denmark), J. Davidsen (Odense, Denmark), S. Shaker (Copenhagen, Denmark), B. Deleuran (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), T. Kragstrup (Aarhus, Denmark)
| |
Late Breaking Abstract - Transcriptomic differences in lung apices and bases in idiopathic pulmonary fibrosis (IPF)
M. Wong (Melbourne, Australia), C. Gamell (Melbourne, Australia), M. Alhamdoosh (Melbourne, Australia), L. Mcmillan (Melbourne, Australia), N. Wilson (Melbourne, Australia), Y. Wee (Melbourne, Australia), M. Staempfli (Melbourne, Australia), G. Westall (Melbourne, Australia), J. Jaffar (Melbourne, Australia)
| |
Late Breaking Abstract - Blood neutrophil levels in IPF patients are significantly associated with quantitative radiological progression
A. Achaiah (Oxford, United Kingdom), E. Fraser (Oxford, United Kingdom), P. Saunders (Oxford, United Kingdom), R. Hoyles (Oxford, United Kingdom), R. Benamore (Oxford, United Kingdom), L. Ho (Oxford, United Kingdom)
| |
Late Breaking Abstract - Data-driven multivariate cohort selection and automated CT scan lung volume measurement identifies disease progression in Idiopathic Pulmonary Fibrosis (IPF)
H. Manners (Cambridge, United Kingdom), T. Mclellan (Cambridge, United Kingdom), K. Kirov (Cambridge, United Kingdom), M. Roberts (Cambridge, United Kingdom), F. Kanavati (Cambridge, United Kingdom), G. Mckenzie (Cambridge, United Kingdom), D. Gallagher (Cambridge, United Kingdom), J. Hainsworth (Cambridge, United Kingdom), D. Dosanjh (Birmingham, United Kingdom), P. Molyneaux (London, United Kingdom), A. Ruggiero (Cambridge, United Kingdom), M. Thillai (Cambridge, United Kingdom)
| |